Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Rating of “Strong Buy” from Brokerages

Posted by Lauren Steadman on Nov 10th, 2025

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) have earned a consensus rating of “Strong Buy” from the six research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a strong buy recommendation to the company.

A number of equities research analysts recently weighed in on ZLDPF shares. Zacks Research upgraded Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 15th. Wells Fargo & Company raised Zealand Pharma A/S to a “strong-buy” rating in a research note on Thursday, July 24th.

Get Our Latest Analysis on Zealand Pharma A/S

Zealand Pharma A/S Price Performance

Shares of OTCMKTS:ZLDPF opened at $67.15 on Monday. The company has a market cap of $4.77 billion, a price-to-earnings ratio of 4.72 and a beta of 0.71. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.09 and a quick ratio of 15.08. The firm has a 50 day simple moving average of $72.64 and a 200 day simple moving average of $65.59. Zealand Pharma A/S has a one year low of $49.98 and a one year high of $126.00.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported $16.06 earnings per share for the quarter, missing analysts’ consensus estimates of $16.72 by ($0.66). The company had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $9.18 billion. Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%. Research analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.